Equity Overview
Price & Market Data
Price: $6.92
Daily Change: +$0.14 / 2.02%
Daily Range: $6.92 - $7.52
Market Cap: $485,205,408
Daily Volume: 6,322
Performance Metrics
1 Week: 13.76%
1 Month: 13.19%
3 Months: 74.29%
6 Months: 188.5%
1 Year: 421.5%
YTD: 85.75%
Company Details
Employees: 40
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.